RayKnowChina Research Map
Shortlist0

HangzhouZhejiang University School of Medicine

Children's Hospital, Zhejiang University School of Medicine

浙江大学医学院附属儿童医院

Listed for 21 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Children's Hospital, Zhejiang University School of Medicine

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatoblastoma肝母细胞瘤1 paper led
  2. Osteosarcoma骨肉瘤5 papers led
  3. Neuroblastoma神经母细胞瘤7 papers led
  4. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病5 papers led
  5. Aplastic anaemia再生障碍性贫血2 papers led
  6. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症8 papers led
  7. Haemophilia A血友病 A0 papers led
  8. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  9. Myasthenia gravis重症肌无力1 paper led1 open trial led
  10. Biliary atresia胆道闭锁2 papers led
  11. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  12. Spinal muscular atrophy脊髓性肌萎缩症2 papers led
  13. Fabry disease法布雷病2 papers led1 open trial led
  14. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  15. Alport syndromeAlport 综合征0 papers led
  16. IgA nephropathyIgA 肾病7 papers led4 open trials led
  17. Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
  18. Congenital diaphragmatic hernia先天性膈疝0 papers led
  19. Hirschsprung disease先天性巨结肠4 papers led
  20. Leber hereditary optic neuropathyLeber 遗传性视神经病变4 papers led
  21. Majeed syndromeMajeed 综合征1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Pompe disease, Behçet disease, Gaucher disease, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Hangzhou for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 5 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025

22 hospitals in Hangzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 7 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 2220242025: 112025

8 hospitals in Hangzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineNephrologyPediatricsMedical oncology
Papers it led7
  1. Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors.2026Cancer research communications
  2. Disruption of the KLHL37-N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models.2025The Journal of clinical investigation
  3. Author(s)' Reply: Is MYCN Overexpression Associated With Poor Outcome in MYCN Non-Amplified Neuroblastomas?2024Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  4. Perioperative complication incidence and risk factors for retroperitoneal neuroblastoma in children: analysis of 571 patients.2024World journal of pediatrics : WJP
  5. Current vaccination status and safety of children with peripheral neuroblastoma in the real-world.2023Frontiers in immunology
  6. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.2023Pathology
  7. Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in MYCN Non-Amplified Neuroblastoma.2023Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
Chinese-language papers (not in the count)1
  1. [Beckwith-Wiedemann syndrome with ganglioneuroblastoma: a case report].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
Earlier papers (2016–2020)6
  1. Pediatric radiation enteritis with intestinal failure: A case report and literature review.2020Medicine
  2. [Neuroblastoma with the expression of cytokeratin: report of a case].2020Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. Comparative Analysis of Flow Cytometry and Cytomorphology for Neuroblastoma Cell Detection in Effusion and Bone Marrow Specimens.2019Fetal and pediatric pathology
  4. The antitumor effect of static and extremely low frequency magnetic fields against nephroblastoma and neuroblastoma.2018Bioelectromagnetics
  5. A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.2017Medicine
  6. Autologous cord blood transplantation for metastatic neuroblastoma.2016Pediatric transplantation
All its trials on ClinicalTrials.gov, any status3
  1. Construction and Validation of an Intelligent Ultrasound Diagnostic System for the Spectrum of Neuroblastoma in ChildrenActive, not recruitingNCT07549425Lead sponsorStart 2026-01
  2. Risk Model for Metastasis Detection of NeuroblastomaEnrolling by invitationNCT06703944Study siteStart 2024-12
  3. Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk NeuroblastomaCompletedNCT05373901Study sitePhase 1Start 2022-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 5 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 2.2%.

Papers led
5
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

2 hospitals in Hangzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

  2. Recruiting
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05579132

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenAntibody & targeted drugsPhiladelphia chromosome & genetics
Departments in papersMedical oncology
Papers it led5
  1. Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease.2025Annals of hematologyFree full text
  2. Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B-Cell Acute Lymphoblastic Leukemia.2025Cancer medicineFree full text
  3. The impact of asparaginase phenotype-related single nucleotide polymorphisms on prognosis in pediatric B-cell precursor acute lymphoblastic leukemia.2025European journal of medical researchFree full text
  4. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.2024Journal of translational medicineFree full text
  5. The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.2023Cancer medicineFree full text
All its trials on ClinicalTrials.gov, any status5
  1. Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical ResearchStatus unknownNCT06393335Lead sponsorEarly phase 1Start 2024-05
  2. MRD Detection by NGS in Pediatric B-ALLCompletedNCT05973032Lead sponsorStart 2018-11
  3. A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRecruitingNCT05334823Study sitePhase 2Start 2022-01
  4. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)RecruitingNCT05579132Study sitePhase 1/Phase 2Start 2022-11
  5. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Hangzhou for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildrenImmunosuppressive treatmentThrombopoietin drugs
Departments in papersMedical oncologyGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 8 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 2.0%.

Papers led
8
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 1120232024: 0020242025: 222025

4 hospitals in Hangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildrenEBV & infection triggersDiagnosis & prognosis
Departments in papersMedical oncology
Papers it led8
  1. Interferon-gamma and C-X-C motif chemokine ligand 9, which is better for haemophagocytic lymphohistiocytosis diagnosis and monitoring?2025British journal of haematology
  2. High Epstein-Barr Virus DNA Load in T Cells Predicts Hemophagocytic Lymphohistiocytosis.2025The Journal of infectious diseases
  3. Comparative study of biomarkers for the early identification of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in infectious mononucleosis.2023BMC infectious diseasesFree full text
  4. Simple Evaluation of Clinical Situation and Subtypes of Pediatric Hemophagocytic Lymphohistiocytosis by Cytokine Patterns.2022Frontiers in immunologyFree full text
  5. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.2022Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  6. Fulminant cytokine release syndrome in a paediatric patient with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis receiving nivolumab treatment.2021Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  7. Diagnostic value of red blood cell distribution width, platelet distribution width, and red blood cell distribution width to platelet ratio in children with hemophagocytic lymphohistiocytosis.2021Journal of clinical laboratory analysisFree full text
  8. Familial hemophagocytic lymphohistiocytosis in a neonate: Case report and literature review.2021MedicineFree full text
Chinese-language papers (not in the count)2
  1. [Advance and perspectives of emapalumab in hemophagocytic lymphohistiocytosis treatment].2025Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Precise diagnosis and treatment of hemophagocytic lymphohistiocytosis guided by cytokine patterns].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic LymphohistiocytosisStatus unknownNCT05491304Lead sponsorPhase 4Start 2022-09
More papers found outside PubMed (not counted)4
  1. Evaluating absolute neutrophil count, IL-6, and IL-10 as rapid diagnostic tools for bacterial infections and septic shock in pediatric leukemia patients2025OncoDaily Medical Journalarticle
  2. Evaluation of the Efficacy of PD-1 Monoclonal Antibody Combined with L-DEP Regimen in Children with Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis and Chronic Active EBV Infection2025OncoDaily Medical Journalarticle
  3. Risk and Response Adapted Treatment Based on Cytokine and Clinical Condition in Hemophagocytic Lymphohistiocytosis2025OncoDaily Medical Journalarticle
  4. Low ratio of IL-10 to IFN-γ and Low IL-10 level indicate good prognosis in Salmonella enterica serovar Typhimurium triggered secondary hemophagocytic lymphohistiocytosis: a case report and literature review2023Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Hangzhou for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Hangzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Co-Occurring Thrombotic Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia in a Child Carrying the Pathogenic SHOC2 c.4A>G (p.Ser2Gly) Variant.2023The American journal of case reports
Earlier papers (2016–2020)1
  1. [A 2-day-old neonate with hyperbilirubinemia and thrombocytopenia].2019Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Hangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07298928

    Age Not stated to 18 years (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPregnancy, children, older adults
Departments in papersNeurology
Papers it led1
  1. Small extracellular vesicle microRNAs in pediatric myasthenia gravis plasma and skeletal muscle.2024Postgraduate medical journal
All its trials on ClinicalTrials.gov, any status1
  1. A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia GravisNot yet recruitingNCT07298928Lead sponsorN/AStart 2026-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 2 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Hangzhou for biliary atresia28 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDisease mechanismsScreening & diagnosis

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

11 hospitals in Hangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. Stress granules in the spinal muscular atrophy and amyotrophic lateral sclerosis: The correlation and promising therapy.2022Neurobiology of disease
Chinese-language papers (not in the count)1
  1. [Pediatric amyotrophic lateral sclerosis caused by FUS gene variation in 2 cases].2024Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 2 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 3.6%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

1 hospital in Hangzhou for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Registry
    NCT07554924

    Age Not stated to 180 days (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology
Papers it led2
  1. Value of creatine kinase and creatinine as biomarkers in nusinersen-treated children with spinal muscular atrophy.2025European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  2. Impact of Nusinersen Treatment on the Independence and Mental Health of School-Aged Patients With Spinal Muscular Atrophy.2025Pediatric neurology
Chinese-language papers (not in the count)3
  1. [Nusinersen in the treatment of 4 children with presymptomatic spinal muscular atrophy].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. Efficacy and safety of salbutamol in treatment of children with later-onset spinal muscular atrophy.2023Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  3. [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status6
  1. Chinese Regional Spinal Muscular Atrophy Patient Registration StudyWithdrawnNCT05631418Lead sponsorStart 2022-11
  2. A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type IRecruitingNCT07554924Study sitePhase 1/Phase 2Start 2026-07
  3. Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1Status unknownNCT05614531Study sitePhase 1/Phase 2Start 2023-02
  4. Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921Study siteStart 2021-11
  5. A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)CompletedNCT04729907Study sitePhase 3Start 2021-04
  6. Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyCompletedNCT04089566Study sitePhase 3Start 2020-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 2 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 2.7%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

7 hospitals in Hangzhou for Fabry disease85 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06539624

    Age 7 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of Medicine; 1 listed hospital as study siteHangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led2
  1. Clinical characteristics and induced pluripotent stem cells (iPSCs) disease model of Fabry disease caused by a novel GLA mutation.2024QJM : monthly journal of the Association of Physicians
  2. Low skeletal muscle mass as an early sign in children with fabry disease.2023Orphanet journal of rare diseases
Chinese-language papers (not in the count)4
  1. [Clinical observation and anti-drug antibody monitoring of enzyme replacement therapy in children with Fabry disease].2025Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  3. [A child of Fabry disease with appendicitis as initial symptom and family screening].2023Zhonghua nei ke za zhi
  4. [Clinical features and enzyme replacement therapy in 4 children with Fabry disease].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status4
  1. Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry DiseaseRecruitingNCT06539624Lead sponsorN/AStart 2024-10
  2. The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry DiseaseNot yet recruitingNCT06819514Study sitePhase 1/Phase 2Start 2025-03
  3. A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry DiseaseCompletedNCT04974749Study sitePhase 3Start 2022-05
  4. Fabry Aim Children Early (ACE) ProjectWithdrawnNCT04965467Study siteStart 2021-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Hangzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Evaluation of the efficacy of corticosteroids in male children with Duchenne muscular dystrophy].2025Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)1
  1. Novel Mutation of the Dystrophin Gene in a Child with Duchenne Muscular Dystrophy.2018Fetal and pediatric pathology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Hangzhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Analysis of Alport syndrome induced by type IV collagen alpha 5 gene mutation in two families].2019Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Learn About How Well BAY 3401016 Works in Adults With Alport SyndromeActive, not recruitingNCT07211685Study sitePhase 2Start 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 7 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.9%.

Papers led
7
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 442025

15 hospitals in Hangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07507201

    Age 3 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  2. Recruiting
    CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
    Phase
    Early phase 1
    Started
    2026-05
    Registry
    NCT07586267

    Age 3 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  3. Recruiting
    Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06792799

    Age 3 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  4. Recruiting
    CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07305116

    Age 3 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrologyPathology / laboratory medicine
Papers it led7
  1. Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study.2026Pediatric nephrology (Berlin, Germany)
  2. Serum cytokine profiles in children with IgA vasculitis with nephritis.2025Biomolecules & biomedicine
  3. Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept.2025CEN case reports
  4. Risk Factors of Histopathological Crescent Formation in Pediatric IgA Vasculitis Nephritis.2025Medicina (Kaunas, Lithuania)
  5. Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis.2025Pediatric nephrology (Berlin, Germany)
  6. Single-cell RNA sequencing of pediatric renal tissues revealed the potential relationship between immunoglobulin A nephropathy and immunoglobulin A vasculitis with nephritis.2024Clinical and translational medicine
  7. Primary IgA nephropathy with nephrotic-range proteinuria in Chinese children.2021Medicine
Earlier papers (2016–2020)1
  1. Evaluation of TGF-β1 and MCP-1 expression and tubulointerstitial fibrosis in children with Henoch-Schönlein purpura nephritis and IgA nephropathy: A clinical correlation.2017Clinics (Sao Paulo, Brazil)
All its trials on ClinicalTrials.gov, any status5
  1. Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseRecruitingNCT07507201Lead sponsorEarly phase 1Start 2026-04
  2. CD19/BCMA UCAR-T for B Cell-Related Autoimmune DiseaseRecruitingNCT07586267Lead sponsorEarly phase 1Start 2026-05
  3. CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune DiseaseRecruitingNCT07305116Lead sponsorPhase 1Start 2025-12
  4. Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune DiseaseRecruitingNCT06792799Lead sponsorEarly phase 1Start 2025-01
  5. RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune DiseasesNot yet recruitingNCT07674147Lead sponsorEarly phase 1Start 2026-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Hangzhou for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Diffuse parenchymal lung diseases in Niemann-Pick disease type C2].2021Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Hangzhou for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 4 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 2.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 112025

3 hospitals in Hangzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 4 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 7.7%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 002025

5 hospitals in Hangzhou for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led4
  1. Abnormal morphology and function in retinal ganglion cells derived from patients-specific iPSCs generated from individuals with Leber's hereditary optic neuropathy.2023Human molecular genetics
  2. Leber's hereditary optic neuropathy-associated ND6 14484T > C mutation caused pleiotropic effects on the complex I, RNA homeostasis, apoptosis and mitophagy.2022Human molecular genetics
  3. Mitochondrial tRNA variants in 811 Chinese probands with Leber's hereditary optic neuropathy.2022Mitochondrion
  4. Assocation Between Leber's Hereditary Optic Neuropathy and MT-ND1 3460G>A Mutation-Induced Alterations in Mitochondrial Function, Apoptosis, and Mitophagy.2021Investigative ophthalmology & visual science
Earlier papers (2016–2020)8
  1. Complex I mutations synergize to worsen the phenotypic expression of Leber's hereditary optic neuropathy.2020The Journal of biological chemistry
  2. PRICKLE3 linked to ATPase biogenesis manifested Leber's hereditary optic neuropathy.2020The Journal of clinical investigation
  3. [Clinical practice guidelines for Leber's hereditary optic neuropathy].2020Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  4. Contribution of mitochondrial ND1 3394T>C mutation to the phenotypic manifestation of Leber's hereditary optic neuropathy.2019Human molecular genetics
  5. Leber's hereditary optic neuropathy (LHON)-associated ND5 12338T > C mutation altered the assembly and function of complex I, apoptosis and mitophagy.2018Human molecular genetics
  6. Leber's hereditary optic neuropathy caused by a mutation in mitochondrial tRNAThr in eight Chinese pedigrees.2018Mitochondrion
  7. Leber's hereditary optic neuropathy is potentially associated with a novel m.5587T>C mutation in two pedigrees.2017Molecular medicine reports
  8. Biochemical evidence for a mitochondrial genetic modifier in the phenotypic manifestation of Leber's hereditary optic neuropathy-associated mitochondrial DNA mutation.2016Human molecular genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Majeed syndrome

Majeed 综合征

Led 1 of the 3 English-language PubMed papers on Majeed syndrome with an author in mainland China, 2021–2025: 33.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Hangzhou for Majeed syndrome7 hospitals in China for Majeed syndrome

No open trial on Majeed syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

浙江大学医学院附属儿童医院

Children's Hospital, Zhejiang University School of Medicine

杭州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Children's Hospital; Children's Hospital of Zhejiang University

Suggest a correctionDownload the data